AKOM – Aerkomm Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Advaxis, Inc. is a clinical-stage biotechnology company, which is focused on the development and commercialization of Listeria monocytogenes (Lm) technology antigen delivery products. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on single antigen and multiple antigen delivery products. The Company’s pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. It has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan